HRP20200080T1 - Terapija raka parvovirusom h-1 u kombinaciji s anti-pd1 antitijelom ili anti pd-l-1 antitijelom - Google Patents
Terapija raka parvovirusom h-1 u kombinaciji s anti-pd1 antitijelom ili anti pd-l-1 antitijelom Download PDFInfo
- Publication number
- HRP20200080T1 HRP20200080T1 HRP20200080TT HRP20200080T HRP20200080T1 HR P20200080 T1 HRP20200080 T1 HR P20200080T1 HR P20200080T T HRP20200080T T HR P20200080TT HR P20200080 T HRP20200080 T HR P20200080T HR P20200080 T1 HRP20200080 T1 HR P20200080T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- antibody
- pharmaceutical combination
- parvovirus
- use according
- Prior art date
Links
- 241000702620 H-1 parvovirus Species 0.000 title claims 5
- 238000011275 oncology therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (12)
1. Farmaceutska kombinacija koja sadrži (a) parvovirus H-1 i (b) anti-PD1 antitijelo ili anti-PD-L1 antitijelo.
2. Farmaceutska kombinacija prema patentnom zahtjevu 1, naznačena time što je anti-PD1-antitijelo pembrolizumab ili nivolumab.
3. Farmaceutska kombinacija prema patentnom zahtjevu 1 ili 2, koja dodatno sadrži jedan ili više dodatnih terapeutskih agensa odabranih od kemioterapeutskih agenasa, bioterapeutskih agenasa, imunogenih agenasa, imuno-stimulatornih citokina i stanica transfektiranih genima koji kodiraju imuno-stimulatorne citokine.
4. Farmaceutska kombinacija definirana u bilo kojem od patentnih zahtjeva 1-3 za upotrebu u postupku za liječenje raka.
5. Farmaceutska kombinacija za upotrebu prema patentnom zahtjevu 4, naznačena time što se (a) parvovirus H-1 i (b) anti-PD1 antitijelo ili anti-PD-L1 antitijelo primjenjuju sekvencijalno.
6. Farmaceutska kombinacija za upotrebu prema patentnom zahtjevu 4 ili 5, naznačena time što je upotreba za liječenje čvrstih tumora, hematoloških karcinoma, i/ili matičnih stanica koje iniciraju rak.
7. Farmaceutska kombinacija za upotrebu prema bilo kojem od patentnih zahtjeva 4 do 6, naznačena time što rak predstavlja rak mozga, rak debelog crijeva, rak mokraćnog mjehura, rak jetre, rak dojke, rak bubrega, karcinom skvamoznih stanica glave/vrata, rak pluća, maligni melanom, rak jajnika, rak pankreasa, rak prostate, rak bubrežnih stanica ili rak želuca.
8. Farmaceutska kombinacija za upotrebu prema patentnom zahtjevu 7, naznačena time što je rak mozga multiformni glioblastom.
9. Farmaceutska kombinacija za upotrebu prema bilo kojem od patentnih zahtjeva 4 do 8, naznačena time što se (a) parvovirus H-1 i/ili (b) anti-PD1 antitijelo ili anti-PD-L1 antitijelo primjenjuju putem intratumorske ili intravenske primjene.
10. Kit koji sadrži prvi kontejner, drugi kontejner i uputstvo u pakiranju, naznačen time što prvi kontejner sadrži najmanje jednu dozu farmaceutske kompozicije koja sadrži parvovirus H-1, drugi kontejner sadrži najmanje jednu dozu farmaceutske kompozicije koja sadrži anti-PD1 antitijelo ili anti-PD-L1 antitijelo, i uputstvo u pakiranju sadrži uputstva za liječenje osobe koja ima rak uporabom farmaceutskih kompozicija.
11. Kit prema patentnom zahtjevu 10, naznačen time što rak predstavlja rak mozga, rak debelog crijeva, rak mokraćnog mjehura, rak jetre, rak dojke, rak bubrega, karcinom skvamoznih stanica glave/vrata, rak pluća, maligni melanom, rak jajnika, rak pankreasa, rak prostate, rak bubrežnih stanica ili rak želuca.
12. Kit prema patentnom zahtjevu 11, naznačen time što je rak mozga multiformni glioblastom.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016163555 | 2016-04-01 | ||
| EP2016020193 | 2016-05-27 | ||
| EP17730376.5A EP3436058B1 (en) | 2016-04-01 | 2017-03-22 | Cancer therapy with parvovirus h-1 combined with an anti-pd1 antibody or anti pd-l-1 antibody |
| PCT/EP2017/056886 WO2017167626A1 (en) | 2016-04-01 | 2017-03-22 | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200080T1 true HRP20200080T1 (hr) | 2020-04-03 |
Family
ID=59067612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200080TT HRP20200080T1 (hr) | 2016-04-01 | 2020-01-17 | Terapija raka parvovirusom h-1 u kombinaciji s anti-pd1 antitijelom ili anti pd-l-1 antitijelom |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3436058B1 (hr) |
| CY (1) | CY1122493T1 (hr) |
| DK (1) | DK3436058T3 (hr) |
| ES (1) | ES2763118T3 (hr) |
| HR (1) | HRP20200080T1 (hr) |
| HU (1) | HUE047237T2 (hr) |
| PL (1) | PL3436058T3 (hr) |
| PT (1) | PT3436058T (hr) |
| RS (1) | RS59768B1 (hr) |
| SI (1) | SI3436058T1 (hr) |
-
2017
- 2017-03-22 DK DK17730376.5T patent/DK3436058T3/da active
- 2017-03-22 RS RS20200023A patent/RS59768B1/sr unknown
- 2017-03-22 SI SI201730163T patent/SI3436058T1/sl unknown
- 2017-03-22 PL PL17730376T patent/PL3436058T3/pl unknown
- 2017-03-22 HU HUE17730376A patent/HUE047237T2/hu unknown
- 2017-03-22 ES ES17730376T patent/ES2763118T3/es active Active
- 2017-03-22 PT PT177303765T patent/PT3436058T/pt unknown
- 2017-03-22 EP EP17730376.5A patent/EP3436058B1/en active Active
-
2020
- 2020-01-14 CY CY20201100031T patent/CY1122493T1/el unknown
- 2020-01-17 HR HRP20200080TT patent/HRP20200080T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2763118T3 (es) | 2020-05-27 |
| EP3436058A1 (en) | 2019-02-06 |
| EP3436058B1 (en) | 2019-10-23 |
| CY1122493T1 (el) | 2021-01-27 |
| DK3436058T3 (da) | 2020-01-20 |
| RS59768B1 (sr) | 2020-02-28 |
| SI3436058T1 (sl) | 2020-02-28 |
| PL3436058T3 (pl) | 2020-04-30 |
| HUE047237T2 (hu) | 2020-04-28 |
| PT3436058T (pt) | 2020-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2954860T3 (es) | Uso de azelnidipina en la preparación de una composición medicinal para el tratamiento de cánceres | |
| HRP20211145T1 (hr) | Novi genetski modificiran virus vakcinije | |
| An et al. | Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo | |
| RU2011146654A (ru) | Способы лечения рака яичников с применением конъюгированного средства | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| JP2019504105A5 (hr) | ||
| JP2020183440A5 (hr) | ||
| Fujita et al. | Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma | |
| Valsecchi et al. | Recent treatment advances and novel therapies in pancreas cancer: a review | |
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| Li et al. | Anticancer effects of morin-7-sulphate sodium, a flavonoid derivative, in mouse melanoma cells | |
| RU2019133787A (ru) | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования | |
| EA200900912A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| Zhang et al. | Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer | |
| RU2017119065A (ru) | Апилимод для применения в лечении рака почек | |
| Gaggianesi et al. | Messing up the cancer stem cell chemoresistance mechanisms supported by tumor microenvironment | |
| Yuan et al. | Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis | |
| MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| Wickstroem et al. | Preclinical combination studies of an FGFR2 targeted thorium-227 conjugate and the ATR inhibitor BAY 1895344 | |
| Lindenblatt et al. | Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака |